Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07480564 · ClinicalTrials.gov registry record · Phase 3
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
A Phase 3 study, sponsored by Taysha Gene Therapies.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT07480564: Recruiting Phase 3 study, sponsored by Taysha Gene Therapies.
NCT07480564 is a Phase 3 study that is actively recruiting participants, run by Taysha Gene Therapies. The registered enrollment target is 3 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07480564, a Phase 3 study, is actively recruiting participants, sponsored by Taysha Gene Therapies.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
Primary Outcome
Safety and Tolerability of TSHA-102 Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
Interventions
- GENETIC TSHA-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2031-06 |
| Phase | Phase 3 |
What NCT07480564 shows while recruiting
NCT07480564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which TSHA-102 is the first listed.
NCT07480564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07480564 about?
NCT07480564 is a clinical study titled "Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome". The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
What is the current status of trial NCT07480564?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2026-05-08. Estimated completion is 2031-06.
What interventions are being tested in trial NCT07480564?
The interventions under investigation include: TSHA-102 (GENETIC).
Who is sponsoring clinical trial NCT07480564?
This trial is sponsored by Taysha Gene Therapies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07480564's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI